Cancer Research SABCS EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurokawa, H.
Right arrow Articles by Arteaga, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurokawa, H.
Right arrow Articles by Arteaga, C. L.
[Cancer Research 60, 5887-5894, October 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells1

Hirokazu Kurokawa, Anne E. G. Lenferink, Jean F. Simpson, Paul I. Pisacane, Mark X. Sliwkowski, James T. Forbes and Carlos L. Arteaga2

Departments of Medicine [H. K., A. E. G. L., J. T. F., C. L. A.], Cell Biology [C. L. A.], and Pathology [J. F. S., J. T. F.], Vanderbilt University School of Medicine, Department of Veteran Affairs Medical Center [C. L. A.] and Vanderbilt-Ingram Cancer Center [J. F. S., C. L. A.], Nashville, Tennessee 37232, and Genentech, Inc. South San Francisco, California 94080 [P. I. P., M. X. S.]

HER2/neu (erbB-2) overexpression has been causally associated with tamoxifen resistance in human breast cancer cells. Forced expression of HER2 in MCF-7 breast cancer cells resulted in mitogen-activated protein kinase (MAPK) hyperactivity and tamoxifen resistance. Inhibition of HER2 and MAPKs with AG1478 and U0126, respectively, as well as dominant-negative MEK-1/2 constructs restored the inhibitory effect of tamoxifen on estrogen receptor (ER)-mediated transcription and cell proliferation. Both AG1478 and U0126 also restored the tamoxifen-mediated association of ER with nuclear receptor corepressor (N-CoR) in the antiestrogen-resistant MCF-7 cells. Treatment with a combination of tamoxifen and a HER2 kinase inhibitor reduced tumor MAPK activity and markedly prevented growth of HER2-overexpressing MCF-7 xenografts in athymic mice. Thus, blockade of HER2 and MAPK signaling may enhance tamoxifen action and abrogate antiestrogen resistance in human breast cancer.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
A. Vivacqua, R. Lappano, P. De Marco, D. Sisci, S. Aquila, F. De Amicis, S. A. W. Fuqua, S. Ando, and M. Maggiolini
G Protein-Coupled Receptor 30 Expression Is Up-Regulated by EGF and TGF{alpha} in Estrogen Receptor {alpha}-Positive Cancer Cells
Mol. Endocrinol., November 1, 2009; 23(11): 1815 - 1826.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ann. Onc., July 1, 2009; 20(7): 1157 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, et al.
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., June 1, 2009; 27(16): 2630 - 2637.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. W. Miller, M. Perez-Torres, A. Narasanna, M. Guix, O. Stal, G. Perez-Tenorio, A. M. Gonzalez-Angulo, B. T. Hennessy, G. B. Mills, J. P. Kennedy, et al.
Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
Cancer Res., May 15, 2009; 69(10): 4192 - 4201.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Generali, F. M. Buffa, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al.
Phosphorylated ER{alpha}, HIF-1{alpha}, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 227 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Pancholi, A. E Lykkesfeldt, C. Hilmi, S. Banerjee, A. Leary, S. Drury, S. Johnston, M. Dowsett, and L.-A. Martin
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2
Endocr. Relat. Cancer, December 1, 2008; 15(4): 985 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
B. Chen, Y. Wang, S. E Kane, and S. Chen
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells
J. Mol. Endocrinol., November 1, 2008; 41(5): 367 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. Yamashita, M. Nishio, T. Toyama, H. Sugiura, N. Kondo, S. Kobayashi, Y. Fujii, and H. Iwase
Low phosphorylation of estrogen receptor {alpha} (ER{alpha}) serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer
Endocr. Relat. Cancer, September 1, 2008; 15(3): 755 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Naresh, A. D. Thor, S. M. Edgerton, K. C. Torkko, R. Kumar, and F. E. Jones
The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
Cancer Res., August 1, 2008; 68(15): 6387 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Generali, S. B. Fox, M. P. Brizzi, G. Allevi, S. Bonardi, S. Aguggini, M. Milani, A. Bersiga, L. Campo, R. Dionisio, et al.
Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2673 - 2680.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
R. S Thomas, N. Sarwar, F. Phoenix, R C. Coombes, and S. Ali
Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-{alpha} activity
J. Mol. Endocrinol., April 1, 2008; 40(4): 173 - 184.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Wang, S. Masri, S. Phung, and S. Chen
The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop
Cancer Res., April 1, 2008; 68(7): 2259 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
Endocr. Rev., April 1, 2008; 29(2): 217 - 233.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Bhoopathi, C. Chetty, S. Kunigal, S. K. Vanamala, J. S. Rao, and S. S. Lakka
Blockade of Tumor Growth Due to Matrix Metalloproteinase-9 Inhibition Is Mediated by Sequential Activation of 1-Integrin, ERK, and NF-{kappa}B
J. Biol. Chem., January 18, 2008; 283(3): 1545 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Wang, S. Dahiya, H. Provencher, B. Muir, E. Carney, K. Coser, T. Shioda, X.-J. Ma, and D. C. Sgroi
The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer
Clin. Cancer Res., November 1, 2007; 13(21): 6327 - 6334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M.S. Bartlett, I. O. Ellis, M. Dowsett, E. A. Mallon, D. A. Cameron, S. Johnston, E. Hall, R. A'Hern, C. Peckitt, J. M. Bliss, et al.
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4423 - 4430.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Beeram, Q-T. Tan, R. Tekmal, D Russell, A Middleton, and L. deGraffenried
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
Ann. Onc., August 1, 2007; 18(8): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al.
Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
J. Clin. Oncol., May 20, 2007; 25(15): 2006 - 2011.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
J Natl Cancer Inst, May 2, 2007; 99(9): 694 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait
Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity
Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-F. Wang, M. Birringer, L.-F. Dong, P. Veprek, P. Low, E. Swettenham, M. Stantic, L.-H. Yuan, R. Zobalova, K. Wu, et al.
A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression
Cancer Res., April 1, 2007; 67(7): 3337 - 3344.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Lehnes, A. D. Winder, C. Alfonso, N. Kasid, M. Simoneaux, H. Summe, E. Morgan, M. C. Iann, J. Duncan, M. Eagan, et al.
The Effect of Estradiol on in Vivo Tumorigenesis Is Modulated by the Human Epidermal Growth Factor Receptor 2/Phosphatidylinositol 3-Kinase/Akt1 Pathway
Endocrinology, March 1, 2007; 148(3): 1171 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Fan, J. Wang, R. J. Santen, and W. Yue
Long-term Treatment with Tamoxifen Facilitates Translocation of Estrogen Receptor {alpha} out of the Nucleus and Enhances its Interaction with EGFR in MCF-7 Breast Cancer Cells
Cancer Res., February 1, 2007; 67(3): 1352 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Massarweh and R. Schiff
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Hiscox, L Morgan, T. Green, and R. I Nicholson
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Cui, I. Parra, M. Zhang, S. G. Hilsenbeck, A. Tsimelzon, T. Furukawa, A. Horii, Z.-Y. Zhang, R. I. Nicholson, and S. A.W. Fuqua
Elevated Expression of Mitogen-Activated Protein Kinase Phosphatase 3 in Breast Tumors: A Mechanism of Tamoxifen Resistance
Cancer Res., June 1, 2006; 66(11): 5950 - 5959.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. Glaros, N. Atanaskova, C. Zhao, D. F. Skafar, and K. B. Reddy
Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen
Mol. Endocrinol., May 1, 2006; 20(5): 996 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Konopleva, W. Zhang, Y.-X. Shi, T. McQueen, T. Tsao, M. Abdelrahim, M. F. Munsell, M. Johansen, D. Yu, T. Madden, et al.
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.
Mol. Cancer Ther., February 1, 2006; 5(2): 317 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Shin, T. Miller, and C. L. Arteaga
ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors
Clin. Cancer Res., February 1, 2006; 12(3): 1008s - 1012s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R.D. Johnston
Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer
Clin. Cancer Res., February 1, 2006; 12(3): 1061s - 1068s.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. K. Pandey, T. S. Udayakumar, X. Lin, D. Sharma, P. S. Shapiro, and J. D. Fondell
Activation of TRAP/Mediator Subunit TRAP220/Med1 Is Regulated by Mitogen-Activated Protein Kinase-Dependent Phosphorylation
Mol. Cell. Biol., December 15, 2005; 25(24): 10695 - 10710.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A. de Matteis, A. Giordano, F. Perrone, and on behalf of the NCI-Naples Breast Cancer Group
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 721 - 747.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Dowsett, J. Cuzick, C. Wale, T. Howell, J. Houghton, and M. Baum
Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study
J. Clin. Oncol., October 20, 2005; 23(30): 7512 - 7517.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
J. Clin. Oncol., October 20, 2005; 23(30): 7721 - 7735.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. R Gunthert, C. Grundker, A. Olota, J. Lasche, N. Eicke, and G. Emons
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen
Eur. J. Endocrinol., October 1, 2005; 153(4): 613 - 625.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. C. Peterson, M. D. Servinsky, A. Christian, Z. Peng, W. Qiu, J. Mann, J. Dicello, and D. L. Huso
Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model
Carcinogenesis, September 1, 2005; 26(9): 1542 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, et al.
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4741 - 4748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Tovey, B. Dunne, C. J. Witton, A. Forsyth, T. G. Cooke, and J. M.S. Bartlett
Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?
Clin. Cancer Res., July 1, 2005; 11(13): 4835 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R I Nicholson, I R Hutcheson, S E Hiscox, J M Knowlden, M Giles, D Barrow, and J M W Gee
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S29 - S36.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Y Zhou, S Eppenberger-Castori, U Eppenberger, and C C Benz
The NF{kappa}B pathway and endocrine-resistant breast cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S37 - S46.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S R D Johnston
Clinical trials of intracellular signal transductions inhibitors for breast cancer -- a strategy to overcome endocrine resistance
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S145 - S157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Huang, J. Groth, K. Sossey-Alaoui, L. Hawthorn, S. Beall, and J. Geradts
Aberrant Expression of Novel and Previously Described Cell Membrane Markers in Human Breast Cancer Cell Lines and Tumors
Clin. Cancer Res., June 15, 2005; 11(12): 4357 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. K. Osborne and R. Schiff
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
J. Clin. Oncol., March 10, 2005; 23(8): 1616 - 1622.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J A Vendrell, I Bieche, C Desmetz, E Badia, S Tozlu, C Nguyen, J C Nicolas, R Lidereau, and P A Cohen
Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines
Endocr. Relat. Cancer, March 1, 2005; 12(1): 75 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Montgomery, E. Makary, K. Schiffman, V. Goodell, and M. L. Disis
Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase
Cancer Res., January 15, 2005; 65(2): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Johnston
Combinations of Endocrine and Biological Agents: Present Status of Therapeutic and Presurgical Investigations
Clin. Cancer Res., January 15, 2005; 11(2): 889s - 899s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Chu, K. Blackwell, S. Chen, and J. Slingerland
The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer
Cancer Res., January 1, 2005; 65(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Sun and F. A. Sinicrope
Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells
Mol. Cancer Ther., January 1, 2005; 4(1): 51 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. deGraffenried, W. E. Friedrichs, D. H. Russell, E. J. Donzis, A. K. Middleton, J. M. Silva, R. A. Roth, and M. Hidalgo
Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity
Clin. Cancer Res., December 1, 2004; 10(23): 8059 - 8067.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study
Clin. Cancer Res., September 1, 2004; 10(17): 5670 - 5676.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. V. Thottassery, Y. Sun, L. Westbrook, S. S. Rentz, M. Manuvakhova, Z. Qu, S. Samuel, R. Upshaw, A. Cunningham, and F. G. Kern
Prolonged Extracellular Signal-Regulated Kinase 1/2 Activation during Fibroblast Growth Factor 1- or Heregulin {beta}1-Induced Antiestrogen-Resistant Growth of Breast Cancer Cells Is Resistant to Mitogen-Activated Protein/Extracellular Regulated Kinase Kinase Inhibitors
Cancer Res., July 1, 2004; 64(13): 4637 - 4647.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Shou, S. Massarweh, C. K. Osborne, A. E. Wakeling, S. Ali, H. Weiss, and R. Schiff
Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer
J Natl Cancer Inst, June 16, 2004; 96(12): 926 - 935.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Ellis
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
Oncologist, June 3, 2004; 9(suppl_3): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Yang, C. J. Barnes, and R. Kumar
Human Epidermal Growth Factor Receptor 2 Status Modulates Subcellular Localization of and Interaction with Estrogen Receptor {alpha} in Breast Cancer Cells
Clin. Cancer Res., June 1, 2004; 10(11): 3621 - 3628.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Tangkeangsirisin, J. Hayashi, and G. Serrero
PC Cell-Derived Growth Factor Mediates Tamoxifen Resistance and Promotes Tumor Growth of Human Breast Cancer Cells
Cancer Res., March 1, 2004; 64(5): 1737 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Argiris, C.-X. Wang, S. G. Whalen, and M. P. DiGiovanna
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Clin. Cancer Res., February 15, 2004; 10(4): 1409 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. E. Konecny, C. A. Wilson, and D. J. Slamon
Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention?
J Natl Cancer Inst, December 17, 2003; 95(24): 1813 - 1815.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Jones
Combining trastuzumab (Herceptin(R)) with hormonal therapy in breast cancer: what can be expected and why?
Ann. Onc., December 1, 2003; 14(12): 1697 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al.
Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Sun, L. Yang, R. I. Feldman, X.-m. Sun, K. N. Bhalla, R. Jove, S. V. Nicosia, and J. Q. Cheng
Activation of Phosphatidylinositol 3-Kinase/Akt Pathway by Androgen through Interaction of p85{alpha}, Androgen Receptor, and Src
J. Biol. Chem., October 31, 2003; 278(44): 42992 - 43000.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
Ann. Onc., September 1, 2003; 14(9): 1346 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Yang, R. Bagheri-Yarmand, S. Balasenthil, G. Hortobagyi, A. A. Sahin, C. J. Barnes, and R. Kumar
HER2 Regulation of Peroxisome Proliferator-activated Receptor {gamma} (PPAR{gamma}) Expression and Sensitivity of Breast Cancer Cells to PPAR{gamma} Ligand Therapy
Clin. Cancer Res., August 1, 2003; 9(8): 3198 - 3203.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. A. deGraffenried, W. E. Friedrichs, L. Fulcher, G. Fernandes, J. M. Silva, J.-M. Peralba, and M. Hidalgo
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity
Ann. Onc., July 1, 2003; 14(7): 1051 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga and J. Baselga
Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice
Clin. Cancer Res., May 1, 2003; 9(5): 1579 - 1589.
[Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
K. Deacon, P. Mistry, J. Chernoff, J. L. Blank, and R. Patel
p38 Mitogen-Activated Protein Kinase Mediates Cell Death and p21-Activated Kinase Mediates Cell Survival during Chemotherapeutic Drug-induced Mitotic Arrest
Mol. Biol. Cell, May 1, 2003; 14(5): 2071 - 2087.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Girault, F. Lerebours, S. Amarir, S. Tozlu, M. Tubiana-Hulin, R. Lidereau, and I. Bieche
Expression Analysis of Estrogen Receptor {alpha} Coregulators in Breast Carcinoma: Evidence That NCOR1 Expression Is Predictive of the Response to Tamoxifen
Clin. Cancer Res., April 1, 2003; 9(4): 1259 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. W. Gee, M. E. Harper, D. Barrow, A. E. Wakeling, and R. I. Nicholson
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
Endocrinology, March 1, 2003; 144(3): 1032 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al.
Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer
Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Schiff, S. Massarweh, J. Shou, and C. K. Osborne
Breast Cancer Endocrine Resistance: How Growth Factor Signaling and Estrogen Receptor Coregulators Modulate Response
Clin. Cancer Res., January 1, 2003; 9(1): 447s - 454s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. Kurokawa and C. L. Arteaga
ErbB (HER) Receptors Can Abrogate Antiestrogen Action in Human Breast Cancer by Multiple Signaling Mechanisms
Clin. Cancer Res., January 1, 2003; 9(1): 511s - 515s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. R. D. Johnston, J. Head, S. Pancholi, S. Detre, L.-A. Martin, I. E. Smith, and M. Dowsett
Integration of Signal Transduction Inhibitors with Endocrine Therapy: An Approach to Overcoming Hormone Resistance in Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 524s - 532s.
[Abstract] [Full Text]

Home page
 Molecular Cancer TherapeuticsHome page
K. Wu, C. Wang, M. D'Amico, R. J. Lee, C. Albanese, R. G. Pestell, and S. Mani
Flavopiridol and Trastuzumab Synergistically Inhibit Proliferation of Breast Cancer Cells: Association with Selective Cooperative Inhibition of Cyclin D1-dependent Kinase and Akt Signaling Pathways
Mol. Cancer Ther., July 1, 2002; 1(9): 695 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Bowman, H. Gabra, S. P. Langdon, A. Lessells, M. Stewart, A. Young, and J. F. Smyth
CA125 Response Is Associated with Estrogen Receptor Expression in a Phase II Trial of Letrozole in Ovarian Cancer: Identification of an Endocrine-sensitive Subgroup
Clin. Cancer Res., July 1, 2002; 8(7): 2233 - 2239.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. G. Keshamouni, R. R. Mattingly, and K. B. Reddy
Mechanism of 17-beta -Estradiol-induced Erk1/2 Activation in Breast Cancer Cells. A ROLE FOR HER2 AND PKC-delta
J. Biol. Chem., June 14, 2002; 277(25): 22558 - 22565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Adeyinka, Y. Nui, T. Cherlet, L. Snell, P. H. Watson, and L. C. Murphy
Activated Mitogen-activated Protein Kinase Expression during Human Breast Tumorigenesis and Breast Cancer Progression
Clin. Cancer Res., June 1, 2002; 8(6): 1747 - 1753.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. K. Scott, C. Marden, F. Xu, L. Kirk, and C. C. Benz
Transcriptional Repression of ErbB2 by Histone Deacetylase Inhibitors Detected by a Genomically Integrated ErbB2 Promoter-reporting Cell Screen
Mol. Cancer Ther., April 1, 2002; 1(6): 385 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
E. R. Simpson and M. Dowsett
Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy
Recent Prog. Horm. Res., January 1, 2002; 57(1): 317 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Dowsett, C. Harper-Wynne, I. Boeddinghaus, J. Salter, M. Hills, M. Dixon, S. Ebbs, G. Gui, N. Sacks, and I. Smith
HER-2 Amplification Impedes the Antiproliferative Effects of Hormone Therapy in Estrogen Receptor-positive Primary Breast Cancer
Cancer Res., December 1, 2001; 61(23): 8452 - 8458.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
I. Hoffmann, E. Eugene, X. Nassif, P.-O. Couraud, and S. Bourdoulous
Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis
J. Cell Biol., October 1, 2001; 155(1): 133 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. E. G. Lenferink, D. Busse, W. M. Flanagan, F. M. Yakes, and C. L. Arteaga
ErbB2/neu Kinase Modulates Cellular p27Kip1 and Cyclin D1 through Multiple Signaling Pathways
Cancer Res., September 1, 2001; 61(17): 6583 - 6591.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. A. McClelland, D. Barrow, T.-A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. W. Gee, and R. I. Nicholson
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)
Endocrinology, July 1, 2001; 142(7): 2776 - 2788.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bagatell, O. Khan, G. Paine-Murrieta, C. W. Taylor, S. Akinaga, and L. Whitesell
Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs: A Ligand-independent Approach to Hormonal Therapy of Breast Cancer
Clin. Cancer Res., July 1, 2001; 7(7): 2076 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-i. Okano and A. K. Rustgi
Paclitaxel Induces Prolonged Activation of the Ras/MEK/ERK Pathway Independently of Activating the Programmed Cell Death Machinery
J. Biol. Chem., May 25, 2001; 276(22): 19555 - 19564.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. C. H. Donovan, A. Milic, and J. M. Slingerland
Constitutive MEK/MAPK Activation Leads to p27Kip1 Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells
J. Biol. Chem., October 26, 2001; 276(44): 40888 - 40895.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.